Loading...
THQM logo

Tchaikapharma High Quality Medicines ADBUL:THQM Stock Report

Market Cap лв1.7b
Share Price
лв18.20
n/a
1Y6.8%
7D1.1%
Portfolio Value
View

Tchaikapharma High Quality Medicines AD

BUL:THQM Stock Report

Market Cap: лв1.7b

Tchaikapharma High Quality Medicines AD (THQM) Stock Overview

Develops, manufactures, and sells medicines in Bulgaria. More details

THQM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

THQM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Tchaikapharma High Quality Medicines AD Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tchaikapharma High Quality Medicines AD
Historical stock prices
Current Share Priceлв18.20
52 Week Highлв18.20
52 Week Lowлв7.75
Beta0.023
1 Month Change1.11%
3 Month Change7.69%
1 Year Change6.81%
3 Year Change24.10%
5 Year Change48.00%
Change since IPO699.04%

Recent News & Updates

Tchaikapharma High Quality Medicines AD's (BUL:THQM) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Feb 26
Tchaikapharma High Quality Medicines AD's (BUL:THQM) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tchaikapharma High Quality Medicines AD (BUL:THQM) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Feb 26
Tchaikapharma High Quality Medicines AD (BUL:THQM) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Recent updates

Tchaikapharma High Quality Medicines AD's (BUL:THQM) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Feb 26
Tchaikapharma High Quality Medicines AD's (BUL:THQM) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tchaikapharma High Quality Medicines AD (BUL:THQM) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Feb 26
Tchaikapharma High Quality Medicines AD (BUL:THQM) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Is Tchaikapharma High Quality Medicines AD (BUL:7TH) A Risky Investment?

Jan 20
Is Tchaikapharma High Quality Medicines AD (BUL:7TH) A Risky Investment?

Can You Imagine How Elated Tchaikapharma High Quality Medicines AD's (BUL:7TH) Shareholders Feel About Its 317% Share Price Gain?

Dec 10
Can You Imagine How Elated Tchaikapharma High Quality Medicines AD's (BUL:7TH) Shareholders Feel About Its 317% Share Price Gain?

Shareholder Returns

THQMBG PharmaceuticalsBG Market
7D1.1%0.3%1.9%
1Y6.8%-3.9%14.6%

Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: THQM underperformed the BG Market which returned 14.6% over the past year.

Price Volatility

Is THQM's price volatile compared to industry and market?
THQM volatility
THQM Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.1%
10% most volatile stocks in BG Market8.4%
10% least volatile stocks in BG Market2.1%

Stable Share Price: THQM's share price has been volatile over the past 3 months compared to the BG market.

Volatility Over Time: Insufficient data to determine THQM's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999209Biser Georgievwww.tchaikapharma.com

Tchaikapharma High Quality Medicines AD develops, manufactures, and sells medicines in Bulgaria. It offers anesthetic, anti-inflammatory and anti-rheumatic, antibiotics, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. The company was founded in 1999 and is headquartered in Sofia, Bulgaria.

Tchaikapharma High Quality Medicines AD Fundamentals Summary

How do Tchaikapharma High Quality Medicines AD's earnings and revenue compare to its market cap?
THQM fundamental statistics
Market capлв1.75b
Earnings (TTM)лв6.75m
Revenue (TTM)лв60.71m
258.7x
P/E Ratio
28.7x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
THQM income statement (TTM)
Revenueлв60.71m
Cost of Revenueлв8.66m
Gross Profitлв52.05m
Other Expensesлв45.31m
Earningsлв6.75m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.07
Gross Margin85.74%
Net Profit Margin11.11%
Debt/Equity Ratio8.4%

How did THQM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 03:12
End of Day Share Price 2025/12/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tchaikapharma High Quality Medicines AD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.